ERBB2 and gastric cancer: Although the median OS of patients with HER-2-positive GC is extended to 14–16 months with addition of trastuzumab in backbone chemotherapy, patients with HER-2 gene amplification or protein overexpression account for only 20% of the overall GC population [3, 4].